Goodwin guided COVID-19 drug maker Pardes Biosciences Inc’s plans to go public through a merger with special purpose acquisition company FS Development Corp. II. The Goodwin team is led by life sciences partners Deepa Rich, Sam Zucker and James Xu. Goodwin partner Rich and Zucker told Reuters in a statement that although the capital markets confirmed to have slowed down this summer, life science companies are still faring well in attracting investments for transactions like SPAC mergers. Read the Reuters article here.
In The Press June 29, 2021